Friday, 17 Aug 2018

You are here

Prevention of HBV Infection: How Are We Doing?

Hepatitis B virus (HBV) infection remains a large cause of morbidity and mortality in worldwide despite it being preventable through screening and vaccination.

In 2016, WHO set out to eliminate HBV infection as a public health threat by 2030. We are far from this goal. Vaccine implementation has been suboptimal in a number of important patient populations, including patients with rheumatologic diseases, as well as other immunocompromising diseases like HIV.

Screening and vaccinating such populations is of utmost importance because hepatitis B surface antigen (HBsAg – chronic infection) and even core antibody (HBcAb – resolved infection) positive patients are at risk of reactivating infection in the setting of immunosuppression, in particular rituximab.

In 2010, survey data was published in Arthritis Care and Research authors queried 1,000 rheumatologists nationwide about familiarity with published guidelines for hepatitis B screening and their awareness of risk of HBV reactivation. While response rate was low they found that depending on the drug 19-53% of physicians were aware of the package insert warning re: HBV reactivation, 42% routinely screened for HBV reactivation prior to starting DMARDs and 69% before biologics. This article is 7 years old but I do not doubt that these low numbers still ring true. (https://buff.ly/2mJ6ftw)

A study published in the Annals of Internal medicine in December 2017 sought to estimate the prevalence of hepatitis B vaccination among U.S. patients with HIV in 2009 through 2012. Out of 18,000 they found that over 1/3 of these patients had missed opportunities to initiation the vaccine series. (https://buff.ly/2DKiPkr)

The current CDC/ACP recommendations state that clinicians should vaccinate all unvaccinated adults at risk including at risk by sexual exposure, percutaneous or mucosal exposure (e.g. healthcare workers), chronic liver disease, ESRD and HIV infection.

While patients requiring immunosuppression are not included here, they are recommended for screening (with HBsAg, HBcAb and HBsAb). What are the ACR guidelines for screening for HBV? They are not exactly clear.

They recommend screening “high-risk” patients receiving leflunomide or methotrexate, and that appropriate evaluation “might include” HBsAg, HBsAb and HbcAb. They mention no recommendation to screen before starting biologics. 

With the growing use of immunosuppression, in particular biologics, we must be aware of the risk of HBV reactivation, which can lead to interruption of treatment and adverse liver consequences, all of which are largely preventable by timely screening and vaccination.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hydroxychloroquine Being Over-Dosed with New Guidelines?

Hydroxychloroquine retinopathy prevention guidelines have revised from ideal body weight-based dosing to actual body weight-based dosing; the question remains whether these have been adopted in clinical practice. A database of nearly 21,000 new HCQ users from a UK general population database studied HCQ dosing and use between 2007 and 2016. Specifically they examined whether users were subjected to excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW).

NSAID Use Around Conception Increases Miscarriage Risk

A study from the American Journal of Obstetrics & Gynecology analyzed pregnant women from the Kaiser Permanente healthcare system and compared newly pregnant women who took non-steroidal anti-inflammatory drugs or acetaminophen or neither showed that using NSAIDs around conception carried a more than four-fold higher risk of early miscarriage. (Citation source: http://bit.ly/2tqNWN6)

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

There have been GI trials with T2T with drug levels but they are not always suggesting that the strategy is superior to usual care. Also, this is really not a common practice in rheumatology.

Methotrexate Update

I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.

Low incidence of methotrexate induced liver abnormalities

Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)

Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.

While being quite effective in oncology, these checkpoint inhibitors have led to the emergence of a quite unique spectrum of rheumatologic conditions presented under the umbrella of immune-related adverse events (irAEs).